← Back to patent-cliff list
HDY-015
Tier C — Watch / tradeHDY-015
Novartis Ag
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：PCSK9, AGT
Indications (approved)：Hypercholesterolaemia, Hypertension
Regional status
US
Phase II
2026-05-29
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of HDY-015?
Approved indications include: Hypercholesterolaemia, Hypertension.
When does the HDY-015 patent expire?
No public expiry year is available for HDY-015 yet; this page updates once verified.
How do I get a quote for HDY-015 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29